Global Oral Polio Vaccines (OPV) Market Growth 2026-2032
The global Oral Polio Vaccines (OPV) market size is predicted to grow from US$ 230 million in 2025 to US$ 270 million in 2032; it is expected to grow at a CAGR of 2.3% from 2026 to 2032.
Oral Polio Vaccines (OPV) are preventive biological products produced from attenuated poliovirus strains through cell culture, virus harvest, clarification, stabilizer formulation, and filling, and are administered orally. The vaccine can replicate locally in the intestine and induce both humoral immunity and intestinal mucosal immunity, thereby helping prevent poliomyelitis infection and interrupt virus transmission within populations. According to the virus types included, OPV can be classified into trivalent, bivalent, monovalent, and novel oral polio vaccines. Among them, bivalent OPV and type-specific novel OPV remain important public health tools in the late stage of global polio control. Compared with injectable inactivated polio vaccines, OPV offers convenient administration, suitability for mass vaccination, strong herd-immunity effects, and high public health accessibility, making it an irreplaceable transmission-interruption tool in the global polio eradication campaign.In 2025, global Oral Polio Vaccines production reached approximately 200 million doses.The average gross profit margin of this product is 55%.
The market value of Oral Polio Vaccines comes from transmission-interruption needs in the late stage of global polio eradication, low-cost mass-coverage advantages, and public health emergency preparedness. Although more countries are strengthening IPV use in routine immunization, OPV still has unique value in inducing intestinal mucosal immunity, rapidly covering pediatric populations, and controlling localized outbreaks. China CDC documents show that the current polio immunization schedule uses a sequential arrangement of IPV and bOPV, reflecting OPV?s continuing role in maintaining herd immunity and reinforcing protection. Internationally, nOPV2 has moved from emergency use toward the WHO prequalification system, and additional manufacturers have obtained prequalification, helping improve global supply resilience and outbreak response efficiency. For manufacturers, OPV is not merely a traditional low-price vaccine, but a strategic public health product connected to national immunization programs, international organization procurement, emergency stockpiles, and the global polio eradication agenda.
The core challenges of the OPV industry come from the safety boundaries of live attenuated virus products, policy substitution pressure, and changes in demand structure. OPV contains replicating attenuated virus, which supports intestinal immunity and herd-level transmission interruption, but in areas with insufficient immunization coverage, vaccine strains may circulate for extended periods and accumulate genetic changes. As a result, global immunization strategies place greater emphasis on combined and scenario-specific use of IPV and OPV. As countries enter the post-eradication stage, routine use of conventional OPV may shrink, while demand becomes more concentrated in supplementary immunization, outbreak response, and international public health procurement. Manufacturers must continuously meet requirements for strain stability, viral titer, sterility control, low-temperature distribution, batch release, and post-marketing monitoring, while managing operating challenges related to government procurement pricing, capacity flexibility, and international certification barriers.
Downstream demand is shifting from universal routine vaccination toward sequential immunization, supplementary immunization in key regions, outbreak control, emergency stockpiling, and international organization procurement. Disease control systems focus on whether OPV can rapidly cover large target pediatric populations, effectively interrupt fecal-oral transmission chains, and coordinate smoothly with IPV-based schedules. International organizations and developing-country markets place greater emphasis on stable supply, field-use convenience, cold-chain accessibility, and mass vaccination efficiency. With the broader deployment of novel OPV, demand will increasingly emphasize type-specific virus control, genetic stability, and rapid response capability. In the future, OPV?s commercial value will not simply be reflected in unit price, but in its public health strategic position, global supply qualification, and irreplaceability within emergency response systems.
LP Information, Inc. (LPI) ' newest research report, the ?Oral Polio Vaccines (OPV) Industry Forecast? looks at past sales and reviews total world Oral Polio Vaccines (OPV) sales in 2025, providing a comprehensive analysis by region and market sector of projected Oral Polio Vaccines (OPV) sales for 2026 through 2032. With Oral Polio Vaccines (OPV) sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Oral Polio Vaccines (OPV) industry.
This Insight Report provides a comprehensive analysis of the global Oral Polio Vaccines (OPV) landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Oral Polio Vaccines (OPV) portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms? unique position in an accelerating global Oral Polio Vaccines (OPV) market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Oral Polio Vaccines (OPV) and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Oral Polio Vaccines (OPV).
This report presents a comprehensive overview, market shares, and growth opportunities of Oral Polio Vaccines (OPV) market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
What is the 10-year outlook for the global Oral Polio Vaccines (OPV) market?
What factors are driving Oral Polio Vaccines (OPV) market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Oral Polio Vaccines (OPV) market opportunities vary by end market size?
How does Oral Polio Vaccines (OPV) break out by Type, by Application?
Oral Polio Vaccines (OPV) are preventive biological products produced from attenuated poliovirus strains through cell culture, virus harvest, clarification, stabilizer formulation, and filling, and are administered orally. The vaccine can replicate locally in the intestine and induce both humoral immunity and intestinal mucosal immunity, thereby helping prevent poliomyelitis infection and interrupt virus transmission within populations. According to the virus types included, OPV can be classified into trivalent, bivalent, monovalent, and novel oral polio vaccines. Among them, bivalent OPV and type-specific novel OPV remain important public health tools in the late stage of global polio control. Compared with injectable inactivated polio vaccines, OPV offers convenient administration, suitability for mass vaccination, strong herd-immunity effects, and high public health accessibility, making it an irreplaceable transmission-interruption tool in the global polio eradication campaign.In 2025, global Oral Polio Vaccines production reached approximately 200 million doses.The average gross profit margin of this product is 55%.
The market value of Oral Polio Vaccines comes from transmission-interruption needs in the late stage of global polio eradication, low-cost mass-coverage advantages, and public health emergency preparedness. Although more countries are strengthening IPV use in routine immunization, OPV still has unique value in inducing intestinal mucosal immunity, rapidly covering pediatric populations, and controlling localized outbreaks. China CDC documents show that the current polio immunization schedule uses a sequential arrangement of IPV and bOPV, reflecting OPV?s continuing role in maintaining herd immunity and reinforcing protection. Internationally, nOPV2 has moved from emergency use toward the WHO prequalification system, and additional manufacturers have obtained prequalification, helping improve global supply resilience and outbreak response efficiency. For manufacturers, OPV is not merely a traditional low-price vaccine, but a strategic public health product connected to national immunization programs, international organization procurement, emergency stockpiles, and the global polio eradication agenda.
The core challenges of the OPV industry come from the safety boundaries of live attenuated virus products, policy substitution pressure, and changes in demand structure. OPV contains replicating attenuated virus, which supports intestinal immunity and herd-level transmission interruption, but in areas with insufficient immunization coverage, vaccine strains may circulate for extended periods and accumulate genetic changes. As a result, global immunization strategies place greater emphasis on combined and scenario-specific use of IPV and OPV. As countries enter the post-eradication stage, routine use of conventional OPV may shrink, while demand becomes more concentrated in supplementary immunization, outbreak response, and international public health procurement. Manufacturers must continuously meet requirements for strain stability, viral titer, sterility control, low-temperature distribution, batch release, and post-marketing monitoring, while managing operating challenges related to government procurement pricing, capacity flexibility, and international certification barriers.
Downstream demand is shifting from universal routine vaccination toward sequential immunization, supplementary immunization in key regions, outbreak control, emergency stockpiling, and international organization procurement. Disease control systems focus on whether OPV can rapidly cover large target pediatric populations, effectively interrupt fecal-oral transmission chains, and coordinate smoothly with IPV-based schedules. International organizations and developing-country markets place greater emphasis on stable supply, field-use convenience, cold-chain accessibility, and mass vaccination efficiency. With the broader deployment of novel OPV, demand will increasingly emphasize type-specific virus control, genetic stability, and rapid response capability. In the future, OPV?s commercial value will not simply be reflected in unit price, but in its public health strategic position, global supply qualification, and irreplaceability within emergency response systems.
LP Information, Inc. (LPI) ' newest research report, the ?Oral Polio Vaccines (OPV) Industry Forecast? looks at past sales and reviews total world Oral Polio Vaccines (OPV) sales in 2025, providing a comprehensive analysis by region and market sector of projected Oral Polio Vaccines (OPV) sales for 2026 through 2032. With Oral Polio Vaccines (OPV) sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Oral Polio Vaccines (OPV) industry.
This Insight Report provides a comprehensive analysis of the global Oral Polio Vaccines (OPV) landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Oral Polio Vaccines (OPV) portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms? unique position in an accelerating global Oral Polio Vaccines (OPV) market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Oral Polio Vaccines (OPV) and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Oral Polio Vaccines (OPV).
This report presents a comprehensive overview, market shares, and growth opportunities of Oral Polio Vaccines (OPV) market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
- Conventional OPV
- Novel OPV
- Monovalent
- Bivalent
- Trivalent
- Oral Drops
- Sugar Pill
- Public
- Private
- Americas
- United States
- Canada
- Mexico
- Brazil
- APAC
- China
- Japan
- Korea
- Southeast Asia
- India
- Australia
- Europe
- Germany
- France
- UK
- Italy
- Russia
- Middle East & Africa
- Egypt
- South Africa
- Israel
- Turkey
- GCC Countries
- Sanofi
- GSK
- Bibcol
- Serum Institute (Bilthoven Biologicals)
- Tiantan Biological
- IMBCA
- Panacea Biotec Ltd
- Bio-Med
- Halfkin Bio-Pharmaceuticals
What is the 10-year outlook for the global Oral Polio Vaccines (OPV) market?
What factors are driving Oral Polio Vaccines (OPV) market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Oral Polio Vaccines (OPV) market opportunities vary by end market size?
How does Oral Polio Vaccines (OPV) break out by Type, by Application?
1 SCOPE OF THE REPORT
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Oral Polio Vaccines (OPV) Annual Sales 2021-2032
2.1.2 World Current & Future Analysis for Oral Polio Vaccines (OPV) by Geographic Region, 2021, 2025 & 2032
2.1.3 World Current & Future Analysis for Oral Polio Vaccines (OPV) by Country/Region, 2021, 2025 & 2032
2.2 Oral Polio Vaccines (OPV) Segment by Type
2.2.1 Conventional OPV
2.2.2 Novel OPV
2.2.3 Oral Polio Vaccines (OPV) Sales by Type
2.2.3.1 Global Oral Polio Vaccines (OPV) Sales Market Share by Type (2021-2026)
2.2.3.2 Global Oral Polio Vaccines (OPV) Revenue and Market Share by Type (2021-2026)
2.2.3.3 Global Oral Polio Vaccines (OPV) Sale Price by Type (2021-2026)
2.3 Oral Polio Vaccines (OPV) Segment by Virus Type
2.3.1 Monovalent
2.3.2 Bivalent
2.3.3 Trivalent
2.3.4 Oral Polio Vaccines (OPV) Sales by Virus Type
2.3.4.1 Global Oral Polio Vaccines (OPV) Sales Market Share by Virus Type (2021-2026)
2.3.4.2 Global Oral Polio Vaccines (OPV) Revenue and Market Share by Virus Type (2021-2026)
2.3.4.3 Global Oral Polio Vaccines (OPV) Sale Price by Virus Type (2021-2026)
2.4 Oral Polio Vaccines (OPV) Segment by Dosage Form
2.4.1 Oral Drops
2.4.2 Sugar Pill
2.4.3 Oral Polio Vaccines (OPV) Sales by Dosage Form
2.4.3.1 Global Oral Polio Vaccines (OPV) Sales Market Share by Dosage Form (2021-2026)
2.4.3.2 Global Oral Polio Vaccines (OPV) Revenue and Market Share by Dosage Form (2021-2026)
2.4.3.3 Global Oral Polio Vaccines (OPV) Sale Price by Dosage Form (2021-2026)
2.5 Oral Polio Vaccines (OPV) Segment by Application
2.5.1 Public
2.5.2 Private
2.5.3 Oral Polio Vaccines (OPV) Sales by Application
2.5.3.1 Global Oral Polio Vaccines (OPV) Sale Market Share by Application (2021-2026)
2.5.3.2 Global Oral Polio Vaccines (OPV) Revenue and Market Share by Application (2021-2026)
2.5.3.3 Global Oral Polio Vaccines (OPV) Sale Price by Application (2021-2026)
3 GLOBAL BY COMPANY
3.1 Global Oral Polio Vaccines (OPV) Breakdown Data by Company
3.1.1 Global Oral Polio Vaccines (OPV) Annual Sales by Company (2021-2026)
3.1.2 Global Oral Polio Vaccines (OPV) Sales Market Share by Company (2021-2026)
3.2 Global Oral Polio Vaccines (OPV) Annual Revenue by Company (2021-2026)
3.2.1 Global Oral Polio Vaccines (OPV) Revenue by Company (2021-2026)
3.2.2 Global Oral Polio Vaccines (OPV) Revenue Market Share by Company (2021-2026)
3.3 Global Oral Polio Vaccines (OPV) Sale Price by Company
3.4 Key Manufacturers Oral Polio Vaccines (OPV) Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Oral Polio Vaccines (OPV) Product Location Distribution
3.4.2 Players Oral Polio Vaccines (OPV) Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy
4 WORLD HISTORIC REVIEW FOR ORAL POLIO VACCINES (OPV) BY GEOGRAPHIC REGION
4.1 World Historic Oral Polio Vaccines (OPV) Market Size by Geographic Region (2021-2026)
4.1.1 Global Oral Polio Vaccines (OPV) Annual Sales by Geographic Region (2021-2026)
4.1.2 Global Oral Polio Vaccines (OPV) Annual Revenue by Geographic Region (2021-2026)
4.2 World Historic Oral Polio Vaccines (OPV) Market Size by Country/Region (2021-2026)
4.2.1 Global Oral Polio Vaccines (OPV) Annual Sales by Country/Region (2021-2026)
4.2.2 Global Oral Polio Vaccines (OPV) Annual Revenue by Country/Region (2021-2026)
4.3 Americas Oral Polio Vaccines (OPV) Sales Growth
4.4 APAC Oral Polio Vaccines (OPV) Sales Growth
4.5 Europe Oral Polio Vaccines (OPV) Sales Growth
4.6 Middle East & Africa Oral Polio Vaccines (OPV) Sales Growth
5 AMERICAS
5.1 Americas Oral Polio Vaccines (OPV) Sales by Country
5.1.1 Americas Oral Polio Vaccines (OPV) Sales by Country (2021-2026)
5.1.2 Americas Oral Polio Vaccines (OPV) Revenue by Country (2021-2026)
5.2 Americas Oral Polio Vaccines (OPV) Sales by Type (2021-2026)
5.3 Americas Oral Polio Vaccines (OPV) Sales by Application (2021-2026)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Oral Polio Vaccines (OPV) Sales by Region
6.1.1 APAC Oral Polio Vaccines (OPV) Sales by Region (2021-2026)
6.1.2 APAC Oral Polio Vaccines (OPV) Revenue by Region (2021-2026)
6.2 APAC Oral Polio Vaccines (OPV) Sales by Type (2021-2026)
6.3 APAC Oral Polio Vaccines (OPV) Sales by Application (2021-2026)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe Oral Polio Vaccines (OPV) by Country
7.1.1 Europe Oral Polio Vaccines (OPV) Sales by Country (2021-2026)
7.1.2 Europe Oral Polio Vaccines (OPV) Revenue by Country (2021-2026)
7.2 Europe Oral Polio Vaccines (OPV) Sales by Type (2021-2026)
7.3 Europe Oral Polio Vaccines (OPV) Sales by Application (2021-2026)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Oral Polio Vaccines (OPV) by Country
8.1.1 Middle East & Africa Oral Polio Vaccines (OPV) Sales by Country (2021-2026)
8.1.2 Middle East & Africa Oral Polio Vaccines (OPV) Revenue by Country (2021-2026)
8.2 Middle East & Africa Oral Polio Vaccines (OPV) Sales by Type (2021-2026)
8.3 Middle East & Africa Oral Polio Vaccines (OPV) Sales by Application (2021-2026)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Oral Polio Vaccines (OPV)
10.3 Manufacturing Process Analysis of Oral Polio Vaccines (OPV)
10.4 Industry Chain Structure of Oral Polio Vaccines (OPV)
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Oral Polio Vaccines (OPV) Distributors
11.3 Oral Polio Vaccines (OPV) Customer
12 WORLD FORECAST REVIEW FOR ORAL POLIO VACCINES (OPV) BY GEOGRAPHIC REGION
12.1 Global Oral Polio Vaccines (OPV) Market Size Forecast by Region
12.1.1 Global Oral Polio Vaccines (OPV) Forecast by Region (2027-2032)
12.1.2 Global Oral Polio Vaccines (OPV) Annual Revenue Forecast by Region (2027-2032)
12.2 Americas Forecast by Country (2027-2032)
12.3 APAC Forecast by Region (2027-2032)
12.4 Europe Forecast by Country (2027-2032)
12.5 Middle East & Africa Forecast by Country (2027-2032)
12.6 Global Oral Polio Vaccines (OPV) Forecast by Type (2027-2032)
12.7 Global Oral Polio Vaccines (OPV) Forecast by Application (2027-2032)
13 KEY PLAYERS ANALYSIS
13.1 Sanofi
13.1.1 Sanofi Company Information
13.1.2 Sanofi Oral Polio Vaccines (OPV) Product Portfolios and Specifications
13.1.3 Sanofi Oral Polio Vaccines (OPV) Sales, Revenue, Price and Gross Margin (2021-2026)
13.1.4 Sanofi Main Business Overview
13.1.5 Sanofi Latest Developments
13.2 GSK
13.2.1 GSK Company Information
13.2.2 GSK Oral Polio Vaccines (OPV) Product Portfolios and Specifications
13.2.3 GSK Oral Polio Vaccines (OPV) Sales, Revenue, Price and Gross Margin (2021-2026)
13.2.4 GSK Main Business Overview
13.2.5 GSK Latest Developments
13.3 Bibcol
13.3.1 Bibcol Company Information
13.3.2 Bibcol Oral Polio Vaccines (OPV) Product Portfolios and Specifications
13.3.3 Bibcol Oral Polio Vaccines (OPV) Sales, Revenue, Price and Gross Margin (2021-2026)
13.3.4 Bibcol Main Business Overview
13.3.5 Bibcol Latest Developments
13.4 Serum Institute (Bilthoven Biologicals)
13.4.1 Serum Institute (Bilthoven Biologicals) Company Information
13.4.2 Serum Institute (Bilthoven Biologicals) Oral Polio Vaccines (OPV) Product Portfolios and Specifications
13.4.3 Serum Institute (Bilthoven Biologicals) Oral Polio Vaccines (OPV) Sales, Revenue, Price and Gross Margin (2021-2026)
13.4.4 Serum Institute (Bilthoven Biologicals) Main Business Overview
13.4.5 Serum Institute (Bilthoven Biologicals) Latest Developments
13.5 Tiantan Biological
13.5.1 Tiantan Biological Company Information
13.5.2 Tiantan Biological Oral Polio Vaccines (OPV) Product Portfolios and Specifications
13.5.3 Tiantan Biological Oral Polio Vaccines (OPV) Sales, Revenue, Price and Gross Margin (2021-2026)
13.5.4 Tiantan Biological Main Business Overview
13.5.5 Tiantan Biological Latest Developments
13.6 IMBCA
13.6.1 IMBCA Company Information
13.6.2 IMBCA Oral Polio Vaccines (OPV) Product Portfolios and Specifications
13.6.3 IMBCA Oral Polio Vaccines (OPV) Sales, Revenue, Price and Gross Margin (2021-2026)
13.6.4 IMBCA Main Business Overview
13.6.5 IMBCA Latest Developments
13.7 Panacea Biotec Ltd
13.7.1 Panacea Biotec Ltd Company Information
13.7.2 Panacea Biotec Ltd Oral Polio Vaccines (OPV) Product Portfolios and Specifications
13.7.3 Panacea Biotec Ltd Oral Polio Vaccines (OPV) Sales, Revenue, Price and Gross Margin (2021-2026)
13.7.4 Panacea Biotec Ltd Main Business Overview
13.7.5 Panacea Biotec Ltd Latest Developments
13.8 Bio-Med
13.8.1 Bio-Med Company Information
13.8.2 Bio-Med Oral Polio Vaccines (OPV) Product Portfolios and Specifications
13.8.3 Bio-Med Oral Polio Vaccines (OPV) Sales, Revenue, Price and Gross Margin (2021-2026)
13.8.4 Bio-Med Main Business Overview
13.8.5 Bio-Med Latest Developments
13.9 Halfkin Bio-Pharmaceuticals
13.9.1 Halfkin Bio-Pharmaceuticals Company Information
13.9.2 Halfkin Bio-Pharmaceuticals Oral Polio Vaccines (OPV) Product Portfolios and Specifications
13.9.3 Halfkin Bio-Pharmaceuticals Oral Polio Vaccines (OPV) Sales, Revenue, Price and Gross Margin (2021-2026)
13.9.4 Halfkin Bio-Pharmaceuticals Main Business Overview
13.9.5 Halfkin Bio-Pharmaceuticals Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Oral Polio Vaccines (OPV) Annual Sales 2021-2032
2.1.2 World Current & Future Analysis for Oral Polio Vaccines (OPV) by Geographic Region, 2021, 2025 & 2032
2.1.3 World Current & Future Analysis for Oral Polio Vaccines (OPV) by Country/Region, 2021, 2025 & 2032
2.2 Oral Polio Vaccines (OPV) Segment by Type
2.2.1 Conventional OPV
2.2.2 Novel OPV
2.2.3 Oral Polio Vaccines (OPV) Sales by Type
2.2.3.1 Global Oral Polio Vaccines (OPV) Sales Market Share by Type (2021-2026)
2.2.3.2 Global Oral Polio Vaccines (OPV) Revenue and Market Share by Type (2021-2026)
2.2.3.3 Global Oral Polio Vaccines (OPV) Sale Price by Type (2021-2026)
2.3 Oral Polio Vaccines (OPV) Segment by Virus Type
2.3.1 Monovalent
2.3.2 Bivalent
2.3.3 Trivalent
2.3.4 Oral Polio Vaccines (OPV) Sales by Virus Type
2.3.4.1 Global Oral Polio Vaccines (OPV) Sales Market Share by Virus Type (2021-2026)
2.3.4.2 Global Oral Polio Vaccines (OPV) Revenue and Market Share by Virus Type (2021-2026)
2.3.4.3 Global Oral Polio Vaccines (OPV) Sale Price by Virus Type (2021-2026)
2.4 Oral Polio Vaccines (OPV) Segment by Dosage Form
2.4.1 Oral Drops
2.4.2 Sugar Pill
2.4.3 Oral Polio Vaccines (OPV) Sales by Dosage Form
2.4.3.1 Global Oral Polio Vaccines (OPV) Sales Market Share by Dosage Form (2021-2026)
2.4.3.2 Global Oral Polio Vaccines (OPV) Revenue and Market Share by Dosage Form (2021-2026)
2.4.3.3 Global Oral Polio Vaccines (OPV) Sale Price by Dosage Form (2021-2026)
2.5 Oral Polio Vaccines (OPV) Segment by Application
2.5.1 Public
2.5.2 Private
2.5.3 Oral Polio Vaccines (OPV) Sales by Application
2.5.3.1 Global Oral Polio Vaccines (OPV) Sale Market Share by Application (2021-2026)
2.5.3.2 Global Oral Polio Vaccines (OPV) Revenue and Market Share by Application (2021-2026)
2.5.3.3 Global Oral Polio Vaccines (OPV) Sale Price by Application (2021-2026)
3 GLOBAL BY COMPANY
3.1 Global Oral Polio Vaccines (OPV) Breakdown Data by Company
3.1.1 Global Oral Polio Vaccines (OPV) Annual Sales by Company (2021-2026)
3.1.2 Global Oral Polio Vaccines (OPV) Sales Market Share by Company (2021-2026)
3.2 Global Oral Polio Vaccines (OPV) Annual Revenue by Company (2021-2026)
3.2.1 Global Oral Polio Vaccines (OPV) Revenue by Company (2021-2026)
3.2.2 Global Oral Polio Vaccines (OPV) Revenue Market Share by Company (2021-2026)
3.3 Global Oral Polio Vaccines (OPV) Sale Price by Company
3.4 Key Manufacturers Oral Polio Vaccines (OPV) Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Oral Polio Vaccines (OPV) Product Location Distribution
3.4.2 Players Oral Polio Vaccines (OPV) Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy
4 WORLD HISTORIC REVIEW FOR ORAL POLIO VACCINES (OPV) BY GEOGRAPHIC REGION
4.1 World Historic Oral Polio Vaccines (OPV) Market Size by Geographic Region (2021-2026)
4.1.1 Global Oral Polio Vaccines (OPV) Annual Sales by Geographic Region (2021-2026)
4.1.2 Global Oral Polio Vaccines (OPV) Annual Revenue by Geographic Region (2021-2026)
4.2 World Historic Oral Polio Vaccines (OPV) Market Size by Country/Region (2021-2026)
4.2.1 Global Oral Polio Vaccines (OPV) Annual Sales by Country/Region (2021-2026)
4.2.2 Global Oral Polio Vaccines (OPV) Annual Revenue by Country/Region (2021-2026)
4.3 Americas Oral Polio Vaccines (OPV) Sales Growth
4.4 APAC Oral Polio Vaccines (OPV) Sales Growth
4.5 Europe Oral Polio Vaccines (OPV) Sales Growth
4.6 Middle East & Africa Oral Polio Vaccines (OPV) Sales Growth
5 AMERICAS
5.1 Americas Oral Polio Vaccines (OPV) Sales by Country
5.1.1 Americas Oral Polio Vaccines (OPV) Sales by Country (2021-2026)
5.1.2 Americas Oral Polio Vaccines (OPV) Revenue by Country (2021-2026)
5.2 Americas Oral Polio Vaccines (OPV) Sales by Type (2021-2026)
5.3 Americas Oral Polio Vaccines (OPV) Sales by Application (2021-2026)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Oral Polio Vaccines (OPV) Sales by Region
6.1.1 APAC Oral Polio Vaccines (OPV) Sales by Region (2021-2026)
6.1.2 APAC Oral Polio Vaccines (OPV) Revenue by Region (2021-2026)
6.2 APAC Oral Polio Vaccines (OPV) Sales by Type (2021-2026)
6.3 APAC Oral Polio Vaccines (OPV) Sales by Application (2021-2026)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe Oral Polio Vaccines (OPV) by Country
7.1.1 Europe Oral Polio Vaccines (OPV) Sales by Country (2021-2026)
7.1.2 Europe Oral Polio Vaccines (OPV) Revenue by Country (2021-2026)
7.2 Europe Oral Polio Vaccines (OPV) Sales by Type (2021-2026)
7.3 Europe Oral Polio Vaccines (OPV) Sales by Application (2021-2026)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Oral Polio Vaccines (OPV) by Country
8.1.1 Middle East & Africa Oral Polio Vaccines (OPV) Sales by Country (2021-2026)
8.1.2 Middle East & Africa Oral Polio Vaccines (OPV) Revenue by Country (2021-2026)
8.2 Middle East & Africa Oral Polio Vaccines (OPV) Sales by Type (2021-2026)
8.3 Middle East & Africa Oral Polio Vaccines (OPV) Sales by Application (2021-2026)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Oral Polio Vaccines (OPV)
10.3 Manufacturing Process Analysis of Oral Polio Vaccines (OPV)
10.4 Industry Chain Structure of Oral Polio Vaccines (OPV)
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Oral Polio Vaccines (OPV) Distributors
11.3 Oral Polio Vaccines (OPV) Customer
12 WORLD FORECAST REVIEW FOR ORAL POLIO VACCINES (OPV) BY GEOGRAPHIC REGION
12.1 Global Oral Polio Vaccines (OPV) Market Size Forecast by Region
12.1.1 Global Oral Polio Vaccines (OPV) Forecast by Region (2027-2032)
12.1.2 Global Oral Polio Vaccines (OPV) Annual Revenue Forecast by Region (2027-2032)
12.2 Americas Forecast by Country (2027-2032)
12.3 APAC Forecast by Region (2027-2032)
12.4 Europe Forecast by Country (2027-2032)
12.5 Middle East & Africa Forecast by Country (2027-2032)
12.6 Global Oral Polio Vaccines (OPV) Forecast by Type (2027-2032)
12.7 Global Oral Polio Vaccines (OPV) Forecast by Application (2027-2032)
13 KEY PLAYERS ANALYSIS
13.1 Sanofi
13.1.1 Sanofi Company Information
13.1.2 Sanofi Oral Polio Vaccines (OPV) Product Portfolios and Specifications
13.1.3 Sanofi Oral Polio Vaccines (OPV) Sales, Revenue, Price and Gross Margin (2021-2026)
13.1.4 Sanofi Main Business Overview
13.1.5 Sanofi Latest Developments
13.2 GSK
13.2.1 GSK Company Information
13.2.2 GSK Oral Polio Vaccines (OPV) Product Portfolios and Specifications
13.2.3 GSK Oral Polio Vaccines (OPV) Sales, Revenue, Price and Gross Margin (2021-2026)
13.2.4 GSK Main Business Overview
13.2.5 GSK Latest Developments
13.3 Bibcol
13.3.1 Bibcol Company Information
13.3.2 Bibcol Oral Polio Vaccines (OPV) Product Portfolios and Specifications
13.3.3 Bibcol Oral Polio Vaccines (OPV) Sales, Revenue, Price and Gross Margin (2021-2026)
13.3.4 Bibcol Main Business Overview
13.3.5 Bibcol Latest Developments
13.4 Serum Institute (Bilthoven Biologicals)
13.4.1 Serum Institute (Bilthoven Biologicals) Company Information
13.4.2 Serum Institute (Bilthoven Biologicals) Oral Polio Vaccines (OPV) Product Portfolios and Specifications
13.4.3 Serum Institute (Bilthoven Biologicals) Oral Polio Vaccines (OPV) Sales, Revenue, Price and Gross Margin (2021-2026)
13.4.4 Serum Institute (Bilthoven Biologicals) Main Business Overview
13.4.5 Serum Institute (Bilthoven Biologicals) Latest Developments
13.5 Tiantan Biological
13.5.1 Tiantan Biological Company Information
13.5.2 Tiantan Biological Oral Polio Vaccines (OPV) Product Portfolios and Specifications
13.5.3 Tiantan Biological Oral Polio Vaccines (OPV) Sales, Revenue, Price and Gross Margin (2021-2026)
13.5.4 Tiantan Biological Main Business Overview
13.5.5 Tiantan Biological Latest Developments
13.6 IMBCA
13.6.1 IMBCA Company Information
13.6.2 IMBCA Oral Polio Vaccines (OPV) Product Portfolios and Specifications
13.6.3 IMBCA Oral Polio Vaccines (OPV) Sales, Revenue, Price and Gross Margin (2021-2026)
13.6.4 IMBCA Main Business Overview
13.6.5 IMBCA Latest Developments
13.7 Panacea Biotec Ltd
13.7.1 Panacea Biotec Ltd Company Information
13.7.2 Panacea Biotec Ltd Oral Polio Vaccines (OPV) Product Portfolios and Specifications
13.7.3 Panacea Biotec Ltd Oral Polio Vaccines (OPV) Sales, Revenue, Price and Gross Margin (2021-2026)
13.7.4 Panacea Biotec Ltd Main Business Overview
13.7.5 Panacea Biotec Ltd Latest Developments
13.8 Bio-Med
13.8.1 Bio-Med Company Information
13.8.2 Bio-Med Oral Polio Vaccines (OPV) Product Portfolios and Specifications
13.8.3 Bio-Med Oral Polio Vaccines (OPV) Sales, Revenue, Price and Gross Margin (2021-2026)
13.8.4 Bio-Med Main Business Overview
13.8.5 Bio-Med Latest Developments
13.9 Halfkin Bio-Pharmaceuticals
13.9.1 Halfkin Bio-Pharmaceuticals Company Information
13.9.2 Halfkin Bio-Pharmaceuticals Oral Polio Vaccines (OPV) Product Portfolios and Specifications
13.9.3 Halfkin Bio-Pharmaceuticals Oral Polio Vaccines (OPV) Sales, Revenue, Price and Gross Margin (2021-2026)
13.9.4 Halfkin Bio-Pharmaceuticals Main Business Overview
13.9.5 Halfkin Bio-Pharmaceuticals Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
LIST OF TABLES
Table 1. Oral Polio Vaccines (OPV) Annual Sales CAGR by Geographic Region (2021, 2025 & 2032) & ($ millions)
Table 2. Oral Polio Vaccines (OPV) Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & ($ millions)
Table 3. Major Players of Conventional OPV
Table 4. Major Players of Novel OPV
Table 5. Global Oral Polio Vaccines (OPV) Sales by Type (2021-2026) & (K Dose)
Table 6. Global Oral Polio Vaccines (OPV) Sales Market Share by Type (2021-2026)
Table 7. Global Oral Polio Vaccines (OPV) Revenue by Type (2021-2026) & ($ million)
Table 8. Global Oral Polio Vaccines (OPV) Revenue Market Share by Type (2021-2026)
Table 9. Global Oral Polio Vaccines (OPV) Sale Price by Type (2021-2026) & (US$/Dose)
Table 10. Major Players of Monovalent
Table 11. Major Players of Bivalent
Table 12. Major Players of Trivalent
Table 13. Global Oral Polio Vaccines (OPV) Sales by Virus Type (2021-2026) & (K Dose)
Table 14. Global Oral Polio Vaccines (OPV) Sales Market Share by Virus Type (2021-2026)
Table 15. Global Oral Polio Vaccines (OPV) Revenue by Virus Type (2021-2026) & ($ million)
Table 16. Global Oral Polio Vaccines (OPV) Revenue Market Share by Virus Type (2021-2026)
Table 17. Global Oral Polio Vaccines (OPV) Sale Price by Virus Type (2021-2026) & (US$/Dose)
Table 18. Major Players of Oral Drops
Table 19. Major Players of Sugar Pill
Table 20. Global Oral Polio Vaccines (OPV) Sales by Dosage Form (2021-2026) & (K Dose)
Table 21. Global Oral Polio Vaccines (OPV) Sales Market Share by Dosage Form (2021-2026)
Table 22. Global Oral Polio Vaccines (OPV) Revenue by Dosage Form (2021-2026) & ($ million)
Table 23. Global Oral Polio Vaccines (OPV) Revenue Market Share by Dosage Form (2021-2026)
Table 24. Global Oral Polio Vaccines (OPV) Sale Price by Dosage Form (2021-2026) & (US$/Dose)
Table 25. Global Oral Polio Vaccines (OPV) Sale by Application (2021-2026) & (K Dose)
Table 26. Global Oral Polio Vaccines (OPV) Sale Market Share by Application (2021-2026)
Table 27. Global Oral Polio Vaccines (OPV) Revenue by Application (2021-2026) & ($ million)
Table 28. Global Oral Polio Vaccines (OPV) Revenue Market Share by Application (2021-2026)
Table 29. Global Oral Polio Vaccines (OPV) Sale Price by Application (2021-2026) & (US$/Dose)
Table 30. Global Oral Polio Vaccines (OPV) Sales by Company (2021-2026) & (K Dose)
Table 31. Global Oral Polio Vaccines (OPV) Sales Market Share by Company (2021-2026)
Table 32. Global Oral Polio Vaccines (OPV) Revenue by Company (2021-2026) & ($ millions)
Table 33. Global Oral Polio Vaccines (OPV) Revenue Market Share by Company (2021-2026)
Table 34. Global Oral Polio Vaccines (OPV) Sale Price by Company (2021-2026) & (US$/Dose)
Table 35. Key Manufacturers Oral Polio Vaccines (OPV) Producing Area Distribution and Sales Area
Table 36. Players Oral Polio Vaccines (OPV) Products Offered
Table 37. Oral Polio Vaccines (OPV) Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
Table 38. New Products and Potential Entrants
Table 39. Market M&A Activity & Strategy
Table 40. Global Oral Polio Vaccines (OPV) Sales by Geographic Region (2021-2026) & (K Dose)
Table 41. Global Oral Polio Vaccines (OPV) Sales Market Share Geographic Region (2021-2026)
Table 42. Global Oral Polio Vaccines (OPV) Revenue by Geographic Region (2021-2026) & ($ millions)
Table 43. Global Oral Polio Vaccines (OPV) Revenue Market Share by Geographic Region (2021-2026)
Table 44. Global Oral Polio Vaccines (OPV) Sales by Country/Region (2021-2026) & (K Dose)
Table 45. Global Oral Polio Vaccines (OPV) Sales Market Share by Country/Region (2021-2026)
Table 46. Global Oral Polio Vaccines (OPV) Revenue by Country/Region (2021-2026) & ($ millions)
Table 47. Global Oral Polio Vaccines (OPV) Revenue Market Share by Country/Region (2021-2026)
Table 48. Americas Oral Polio Vaccines (OPV) Sales by Country (2021-2026) & (K Dose)
Table 49. Americas Oral Polio Vaccines (OPV) Sales Market Share by Country (2021-2026)
Table 50. Americas Oral Polio Vaccines (OPV) Revenue by Country (2021-2026) & ($ millions)
Table 51. Americas Oral Polio Vaccines (OPV) Sales by Type (2021-2026) & (K Dose)
Table 52. Americas Oral Polio Vaccines (OPV) Sales by Application (2021-2026) & (K Dose)
Table 53. APAC Oral Polio Vaccines (OPV) Sales by Region (2021-2026) & (K Dose)
Table 54. APAC Oral Polio Vaccines (OPV) Sales Market Share by Region (2021-2026)
Table 55. APAC Oral Polio Vaccines (OPV) Revenue by Region (2021-2026) & ($ millions)
Table 56. APAC Oral Polio Vaccines (OPV) Sales by Type (2021-2026) & (K Dose)
Table 57. APAC Oral Polio Vaccines (OPV) Sales by Application (2021-2026) & (K Dose)
Table 58. Europe Oral Polio Vaccines (OPV) Sales by Country (2021-2026) & (K Dose)
Table 59. Europe Oral Polio Vaccines (OPV) Revenue by Country (2021-2026) & ($ millions)
Table 60. Europe Oral Polio Vaccines (OPV) Sales by Type (2021-2026) & (K Dose)
Table 61. Europe Oral Polio Vaccines (OPV) Sales by Application (2021-2026) & (K Dose)
Table 62. Middle East & Africa Oral Polio Vaccines (OPV) Sales by Country (2021-2026) & (K Dose)
Table 63. Middle East & Africa Oral Polio Vaccines (OPV) Revenue Market Share by Country (2021-2026)
Table 64. Middle East & Africa Oral Polio Vaccines (OPV) Sales by Type (2021-2026) & (K Dose)
Table 65. Middle East & Africa Oral Polio Vaccines (OPV) Sales by Application (2021-2026) & (K Dose)
Table 66. Key Market Drivers & Growth Opportunities of Oral Polio Vaccines (OPV)
Table 67. Key Market Challenges & Risks of Oral Polio Vaccines (OPV)
Table 68. Key Industry Trends of Oral Polio Vaccines (OPV)
Table 69. Oral Polio Vaccines (OPV) Raw Material
Table 70. Key Suppliers of Raw Materials
Table 71. Oral Polio Vaccines (OPV) Distributors List
Table 72. Oral Polio Vaccines (OPV) Customer List
Table 73. Global Oral Polio Vaccines (OPV) Sales Forecast by Region (2027-2032) & (K Dose)
Table 74. Global Oral Polio Vaccines (OPV) Revenue Forecast by Region (2027-2032) & ($ millions)
Table 75. Americas Oral Polio Vaccines (OPV) Sales Forecast by Country (2027-2032) & (K Dose)
Table 76. Americas Oral Polio Vaccines (OPV) Annual Revenue Forecast by Country (2027-2032) & ($ millions)
Table 77. APAC Oral Polio Vaccines (OPV) Sales Forecast by Region (2027-2032) & (K Dose)
Table 78. APAC Oral Polio Vaccines (OPV) Annual Revenue Forecast by Region (2027-2032) & ($ millions)
Table 79. Europe Oral Polio Vaccines (OPV) Sales Forecast by Country (2027-2032) & (K Dose)
Table 80. Europe Oral Polio Vaccines (OPV) Revenue Forecast by Country (2027-2032) & ($ millions)
Table 81. Middle East & Africa Oral Polio Vaccines (OPV) Sales Forecast by Country (2027-2032) & (K Dose)
Table 82. Middle East & Africa Oral Polio Vaccines (OPV) Revenue Forecast by Country (2027-2032) & ($ millions)
Table 83. Global Oral Polio Vaccines (OPV) Sales Forecast by Type (2027-2032) & (K Dose)
Table 84. Global Oral Polio Vaccines (OPV) Revenue Forecast by Type (2027-2032) & ($ millions)
Table 85. Global Oral Polio Vaccines (OPV) Sales Forecast by Application (2027-2032) & (K Dose)
Table 86. Global Oral Polio Vaccines (OPV) Revenue Forecast by Application (2027-2032) & ($ millions)
Table 87. Sanofi Basic Information, Oral Polio Vaccines (OPV) Manufacturing Base, Sales Area and Its Competitors
Table 88. Sanofi Oral Polio Vaccines (OPV) Product Portfolios and Specifications
Table 89. Sanofi Oral Polio Vaccines (OPV) Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 90. Sanofi Main Business
Table 91. Sanofi Latest Developments
Table 92. GSK Basic Information, Oral Polio Vaccines (OPV) Manufacturing Base, Sales Area and Its Competitors
Table 93. GSK Oral Polio Vaccines (OPV) Product Portfolios and Specifications
Table 94. GSK Oral Polio Vaccines (OPV) Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 95. GSK Main Business
Table 96. GSK Latest Developments
Table 97. Bibcol Basic Information, Oral Polio Vaccines (OPV) Manufacturing Base, Sales Area and Its Competitors
Table 98. Bibcol Oral Polio Vaccines (OPV) Product Portfolios and Specifications
Table 99. Bibcol Oral Polio Vaccines (OPV) Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 100. Bibcol Main Business
Table 101. Bibcol Latest Developments
Table 102. Serum?Institute?(Bilthoven?Biologicals) Basic Information, Oral Polio Vaccines (OPV) Manufacturing Base, Sales Area and Its Competitors
Table 103. Serum?Institute?(Bilthoven?Biologicals) Oral Polio Vaccines (OPV) Product Portfolios and Specifications
Table 104. Serum?Institute?(Bilthoven?Biologicals) Oral Polio Vaccines (OPV) Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 105. Serum?Institute?(Bilthoven?Biologicals) Main Business
Table 106. Serum?Institute?(Bilthoven?Biologicals) Latest Developments
Table 107. Tiantan Biological Basic Information, Oral Polio Vaccines (OPV) Manufacturing Base, Sales Area and Its Competitors
Table 108. Tiantan Biological Oral Polio Vaccines (OPV) Product Portfolios and Specifications
Table 109. Tiantan Biological Oral Polio Vaccines (OPV) Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 110. Tiantan Biological Main Business
Table 111. Tiantan Biological Latest Developments
Table 112. IMBCA Basic Information, Oral Polio Vaccines (OPV) Manufacturing Base, Sales Area and Its Competitors
Table 113. IMBCA Oral Polio Vaccines (OPV) Product Portfolios and Specifications
Table 114. IMBCA Oral Polio Vaccines (OPV) Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 115. IMBCA Main Business
Table 116. IMBCA Latest Developments
Table 117. Panacea Biotec Ltd Basic Information, Oral Polio Vaccines (OPV) Manufacturing Base, Sales Area and Its Competitors
Table 118. Panacea Biotec Ltd Oral Polio Vaccines (OPV) Product Portfolios and Specifications
Table 119. Panacea Biotec Ltd Oral Polio Vaccines (OPV) Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 120. Panacea Biotec Ltd Main Business
Table 121. Panacea Biotec Ltd Latest Developments
Table 122. Bio-Med Basic Information, Oral Polio Vaccines (OPV) Manufacturing Base, Sales Area and Its Competitors
Table 123. Bio-Med Oral Polio Vaccines (OPV) Product Portfolios and Specifications
Table 124. Bio-Med Oral Polio Vaccines (OPV) Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 125. Bio-Med Main Business
Table 126. Bio-Med Latest Developments
Table 127. Halfkin Bio-Pharmaceuticals Basic Information, Oral Polio Vaccines (OPV) Manufacturing Base, Sales Area and Its Competitors
Table 128. Halfkin Bio-Pharmaceuticals Oral Polio Vaccines (OPV) Product Portfolios and Specifications
Table 129. Halfkin Bio-Pharmaceuticals Oral Polio Vaccines (OPV) Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 130. Halfkin Bio-Pharmaceuticals Main Business
Table 131. Halfkin Bio-Pharmaceuticals Latest Developments
Table 1. Oral Polio Vaccines (OPV) Annual Sales CAGR by Geographic Region (2021, 2025 & 2032) & ($ millions)
Table 2. Oral Polio Vaccines (OPV) Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & ($ millions)
Table 3. Major Players of Conventional OPV
Table 4. Major Players of Novel OPV
Table 5. Global Oral Polio Vaccines (OPV) Sales by Type (2021-2026) & (K Dose)
Table 6. Global Oral Polio Vaccines (OPV) Sales Market Share by Type (2021-2026)
Table 7. Global Oral Polio Vaccines (OPV) Revenue by Type (2021-2026) & ($ million)
Table 8. Global Oral Polio Vaccines (OPV) Revenue Market Share by Type (2021-2026)
Table 9. Global Oral Polio Vaccines (OPV) Sale Price by Type (2021-2026) & (US$/Dose)
Table 10. Major Players of Monovalent
Table 11. Major Players of Bivalent
Table 12. Major Players of Trivalent
Table 13. Global Oral Polio Vaccines (OPV) Sales by Virus Type (2021-2026) & (K Dose)
Table 14. Global Oral Polio Vaccines (OPV) Sales Market Share by Virus Type (2021-2026)
Table 15. Global Oral Polio Vaccines (OPV) Revenue by Virus Type (2021-2026) & ($ million)
Table 16. Global Oral Polio Vaccines (OPV) Revenue Market Share by Virus Type (2021-2026)
Table 17. Global Oral Polio Vaccines (OPV) Sale Price by Virus Type (2021-2026) & (US$/Dose)
Table 18. Major Players of Oral Drops
Table 19. Major Players of Sugar Pill
Table 20. Global Oral Polio Vaccines (OPV) Sales by Dosage Form (2021-2026) & (K Dose)
Table 21. Global Oral Polio Vaccines (OPV) Sales Market Share by Dosage Form (2021-2026)
Table 22. Global Oral Polio Vaccines (OPV) Revenue by Dosage Form (2021-2026) & ($ million)
Table 23. Global Oral Polio Vaccines (OPV) Revenue Market Share by Dosage Form (2021-2026)
Table 24. Global Oral Polio Vaccines (OPV) Sale Price by Dosage Form (2021-2026) & (US$/Dose)
Table 25. Global Oral Polio Vaccines (OPV) Sale by Application (2021-2026) & (K Dose)
Table 26. Global Oral Polio Vaccines (OPV) Sale Market Share by Application (2021-2026)
Table 27. Global Oral Polio Vaccines (OPV) Revenue by Application (2021-2026) & ($ million)
Table 28. Global Oral Polio Vaccines (OPV) Revenue Market Share by Application (2021-2026)
Table 29. Global Oral Polio Vaccines (OPV) Sale Price by Application (2021-2026) & (US$/Dose)
Table 30. Global Oral Polio Vaccines (OPV) Sales by Company (2021-2026) & (K Dose)
Table 31. Global Oral Polio Vaccines (OPV) Sales Market Share by Company (2021-2026)
Table 32. Global Oral Polio Vaccines (OPV) Revenue by Company (2021-2026) & ($ millions)
Table 33. Global Oral Polio Vaccines (OPV) Revenue Market Share by Company (2021-2026)
Table 34. Global Oral Polio Vaccines (OPV) Sale Price by Company (2021-2026) & (US$/Dose)
Table 35. Key Manufacturers Oral Polio Vaccines (OPV) Producing Area Distribution and Sales Area
Table 36. Players Oral Polio Vaccines (OPV) Products Offered
Table 37. Oral Polio Vaccines (OPV) Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
Table 38. New Products and Potential Entrants
Table 39. Market M&A Activity & Strategy
Table 40. Global Oral Polio Vaccines (OPV) Sales by Geographic Region (2021-2026) & (K Dose)
Table 41. Global Oral Polio Vaccines (OPV) Sales Market Share Geographic Region (2021-2026)
Table 42. Global Oral Polio Vaccines (OPV) Revenue by Geographic Region (2021-2026) & ($ millions)
Table 43. Global Oral Polio Vaccines (OPV) Revenue Market Share by Geographic Region (2021-2026)
Table 44. Global Oral Polio Vaccines (OPV) Sales by Country/Region (2021-2026) & (K Dose)
Table 45. Global Oral Polio Vaccines (OPV) Sales Market Share by Country/Region (2021-2026)
Table 46. Global Oral Polio Vaccines (OPV) Revenue by Country/Region (2021-2026) & ($ millions)
Table 47. Global Oral Polio Vaccines (OPV) Revenue Market Share by Country/Region (2021-2026)
Table 48. Americas Oral Polio Vaccines (OPV) Sales by Country (2021-2026) & (K Dose)
Table 49. Americas Oral Polio Vaccines (OPV) Sales Market Share by Country (2021-2026)
Table 50. Americas Oral Polio Vaccines (OPV) Revenue by Country (2021-2026) & ($ millions)
Table 51. Americas Oral Polio Vaccines (OPV) Sales by Type (2021-2026) & (K Dose)
Table 52. Americas Oral Polio Vaccines (OPV) Sales by Application (2021-2026) & (K Dose)
Table 53. APAC Oral Polio Vaccines (OPV) Sales by Region (2021-2026) & (K Dose)
Table 54. APAC Oral Polio Vaccines (OPV) Sales Market Share by Region (2021-2026)
Table 55. APAC Oral Polio Vaccines (OPV) Revenue by Region (2021-2026) & ($ millions)
Table 56. APAC Oral Polio Vaccines (OPV) Sales by Type (2021-2026) & (K Dose)
Table 57. APAC Oral Polio Vaccines (OPV) Sales by Application (2021-2026) & (K Dose)
Table 58. Europe Oral Polio Vaccines (OPV) Sales by Country (2021-2026) & (K Dose)
Table 59. Europe Oral Polio Vaccines (OPV) Revenue by Country (2021-2026) & ($ millions)
Table 60. Europe Oral Polio Vaccines (OPV) Sales by Type (2021-2026) & (K Dose)
Table 61. Europe Oral Polio Vaccines (OPV) Sales by Application (2021-2026) & (K Dose)
Table 62. Middle East & Africa Oral Polio Vaccines (OPV) Sales by Country (2021-2026) & (K Dose)
Table 63. Middle East & Africa Oral Polio Vaccines (OPV) Revenue Market Share by Country (2021-2026)
Table 64. Middle East & Africa Oral Polio Vaccines (OPV) Sales by Type (2021-2026) & (K Dose)
Table 65. Middle East & Africa Oral Polio Vaccines (OPV) Sales by Application (2021-2026) & (K Dose)
Table 66. Key Market Drivers & Growth Opportunities of Oral Polio Vaccines (OPV)
Table 67. Key Market Challenges & Risks of Oral Polio Vaccines (OPV)
Table 68. Key Industry Trends of Oral Polio Vaccines (OPV)
Table 69. Oral Polio Vaccines (OPV) Raw Material
Table 70. Key Suppliers of Raw Materials
Table 71. Oral Polio Vaccines (OPV) Distributors List
Table 72. Oral Polio Vaccines (OPV) Customer List
Table 73. Global Oral Polio Vaccines (OPV) Sales Forecast by Region (2027-2032) & (K Dose)
Table 74. Global Oral Polio Vaccines (OPV) Revenue Forecast by Region (2027-2032) & ($ millions)
Table 75. Americas Oral Polio Vaccines (OPV) Sales Forecast by Country (2027-2032) & (K Dose)
Table 76. Americas Oral Polio Vaccines (OPV) Annual Revenue Forecast by Country (2027-2032) & ($ millions)
Table 77. APAC Oral Polio Vaccines (OPV) Sales Forecast by Region (2027-2032) & (K Dose)
Table 78. APAC Oral Polio Vaccines (OPV) Annual Revenue Forecast by Region (2027-2032) & ($ millions)
Table 79. Europe Oral Polio Vaccines (OPV) Sales Forecast by Country (2027-2032) & (K Dose)
Table 80. Europe Oral Polio Vaccines (OPV) Revenue Forecast by Country (2027-2032) & ($ millions)
Table 81. Middle East & Africa Oral Polio Vaccines (OPV) Sales Forecast by Country (2027-2032) & (K Dose)
Table 82. Middle East & Africa Oral Polio Vaccines (OPV) Revenue Forecast by Country (2027-2032) & ($ millions)
Table 83. Global Oral Polio Vaccines (OPV) Sales Forecast by Type (2027-2032) & (K Dose)
Table 84. Global Oral Polio Vaccines (OPV) Revenue Forecast by Type (2027-2032) & ($ millions)
Table 85. Global Oral Polio Vaccines (OPV) Sales Forecast by Application (2027-2032) & (K Dose)
Table 86. Global Oral Polio Vaccines (OPV) Revenue Forecast by Application (2027-2032) & ($ millions)
Table 87. Sanofi Basic Information, Oral Polio Vaccines (OPV) Manufacturing Base, Sales Area and Its Competitors
Table 88. Sanofi Oral Polio Vaccines (OPV) Product Portfolios and Specifications
Table 89. Sanofi Oral Polio Vaccines (OPV) Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 90. Sanofi Main Business
Table 91. Sanofi Latest Developments
Table 92. GSK Basic Information, Oral Polio Vaccines (OPV) Manufacturing Base, Sales Area and Its Competitors
Table 93. GSK Oral Polio Vaccines (OPV) Product Portfolios and Specifications
Table 94. GSK Oral Polio Vaccines (OPV) Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 95. GSK Main Business
Table 96. GSK Latest Developments
Table 97. Bibcol Basic Information, Oral Polio Vaccines (OPV) Manufacturing Base, Sales Area and Its Competitors
Table 98. Bibcol Oral Polio Vaccines (OPV) Product Portfolios and Specifications
Table 99. Bibcol Oral Polio Vaccines (OPV) Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 100. Bibcol Main Business
Table 101. Bibcol Latest Developments
Table 102. Serum?Institute?(Bilthoven?Biologicals) Basic Information, Oral Polio Vaccines (OPV) Manufacturing Base, Sales Area and Its Competitors
Table 103. Serum?Institute?(Bilthoven?Biologicals) Oral Polio Vaccines (OPV) Product Portfolios and Specifications
Table 104. Serum?Institute?(Bilthoven?Biologicals) Oral Polio Vaccines (OPV) Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 105. Serum?Institute?(Bilthoven?Biologicals) Main Business
Table 106. Serum?Institute?(Bilthoven?Biologicals) Latest Developments
Table 107. Tiantan Biological Basic Information, Oral Polio Vaccines (OPV) Manufacturing Base, Sales Area and Its Competitors
Table 108. Tiantan Biological Oral Polio Vaccines (OPV) Product Portfolios and Specifications
Table 109. Tiantan Biological Oral Polio Vaccines (OPV) Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 110. Tiantan Biological Main Business
Table 111. Tiantan Biological Latest Developments
Table 112. IMBCA Basic Information, Oral Polio Vaccines (OPV) Manufacturing Base, Sales Area and Its Competitors
Table 113. IMBCA Oral Polio Vaccines (OPV) Product Portfolios and Specifications
Table 114. IMBCA Oral Polio Vaccines (OPV) Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 115. IMBCA Main Business
Table 116. IMBCA Latest Developments
Table 117. Panacea Biotec Ltd Basic Information, Oral Polio Vaccines (OPV) Manufacturing Base, Sales Area and Its Competitors
Table 118. Panacea Biotec Ltd Oral Polio Vaccines (OPV) Product Portfolios and Specifications
Table 119. Panacea Biotec Ltd Oral Polio Vaccines (OPV) Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 120. Panacea Biotec Ltd Main Business
Table 121. Panacea Biotec Ltd Latest Developments
Table 122. Bio-Med Basic Information, Oral Polio Vaccines (OPV) Manufacturing Base, Sales Area and Its Competitors
Table 123. Bio-Med Oral Polio Vaccines (OPV) Product Portfolios and Specifications
Table 124. Bio-Med Oral Polio Vaccines (OPV) Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 125. Bio-Med Main Business
Table 126. Bio-Med Latest Developments
Table 127. Halfkin Bio-Pharmaceuticals Basic Information, Oral Polio Vaccines (OPV) Manufacturing Base, Sales Area and Its Competitors
Table 128. Halfkin Bio-Pharmaceuticals Oral Polio Vaccines (OPV) Product Portfolios and Specifications
Table 129. Halfkin Bio-Pharmaceuticals Oral Polio Vaccines (OPV) Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 130. Halfkin Bio-Pharmaceuticals Main Business
Table 131. Halfkin Bio-Pharmaceuticals Latest Developments
LIST OF FIGURES
Figure 1. Picture of Oral Polio Vaccines (OPV)
Figure 2. Oral Polio Vaccines (OPV) Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Oral Polio Vaccines (OPV) Sales Growth Rate 2021-2032 (K Dose)
Figure 7. Global Oral Polio Vaccines (OPV) Revenue Growth Rate 2021-2032 ($ millions)
Figure 8. Oral Polio Vaccines (OPV) Sales by Geographic Region (2021, 2025 & 2032) & ($ millions)
Figure 9. Oral Polio Vaccines (OPV) Sales Market Share by Country/Region (2025)
Figure 10. Oral Polio Vaccines (OPV) Sales Market Share by Country/Region (2021, 2025 & 2032)
Figure 11. Product Picture of Conventional OPV
Figure 12. Product Picture of Novel OPV
Figure 13. Global Oral Polio Vaccines (OPV) Sales Market Share by Type in 2026
Figure 14. Global Oral Polio Vaccines (OPV) Revenue Market Share by Type (2021-2026)
Figure 15. Product Picture of Monovalent
Figure 16. Product Picture of Bivalent
Figure 17. Product Picture of Trivalent
Figure 18. Global Oral Polio Vaccines (OPV) Sales Market Share by Virus Type in 2026
Figure 19. Global Oral Polio Vaccines (OPV) Revenue Market Share by Virus Type (2021-2026)
Figure 20. Product Picture of Oral Drops
Figure 21. Product Picture of Sugar Pill
Figure 22. Global Oral Polio Vaccines (OPV) Sales Market Share by Dosage Form in 2026
Figure 23. Global Oral Polio Vaccines (OPV) Revenue Market Share by Dosage Form (2021-2026)
Figure 24. Oral Polio Vaccines (OPV) Consumed in Public
Figure 25. Global Oral Polio Vaccines (OPV) Market: Public (2021-2026) & (K Dose)
Figure 26. Oral Polio Vaccines (OPV) Consumed in Private
Figure 27. Global Oral Polio Vaccines (OPV) Market: Private (2021-2026) & (K Dose)
Figure 28. Global Oral Polio Vaccines (OPV) Sale Market Share by Application (2025)
Figure 29. Global Oral Polio Vaccines (OPV) Revenue Market Share by Application in 2025
Figure 30. Oral Polio Vaccines (OPV) Sales by Company in 2025 (K Dose)
Figure 31. Global Oral Polio Vaccines (OPV) Sales Market Share by Company in 2025
Figure 32. Oral Polio Vaccines (OPV) Revenue by Company in 2025 ($ millions)
Figure 33. Global Oral Polio Vaccines (OPV) Revenue Market Share by Company in 2025
Figure 34. Global Oral Polio Vaccines (OPV) Sales Market Share by Geographic Region (2021-2026)
Figure 35. Global Oral Polio Vaccines (OPV) Revenue Market Share by Geographic Region in 2025
Figure 36. Americas Oral Polio Vaccines (OPV) Sales 2021-2026 (K Dose)
Figure 37. Americas Oral Polio Vaccines (OPV) Revenue 2021-2026 ($ millions)
Figure 38. APAC Oral Polio Vaccines (OPV) Sales 2021-2026 (K Dose)
Figure 39. APAC Oral Polio Vaccines (OPV) Revenue 2021-2026 ($ millions)
Figure 40. Europe Oral Polio Vaccines (OPV) Sales 2021-2026 (K Dose)
Figure 41. Europe Oral Polio Vaccines (OPV) Revenue 2021-2026 ($ millions)
Figure 42. Middle East & Africa Oral Polio Vaccines (OPV) Sales 2021-2026 (K Dose)
Figure 43. Middle East & Africa Oral Polio Vaccines (OPV) Revenue 2021-2026 ($ millions)
Figure 44. Americas Oral Polio Vaccines (OPV) Sales Market Share by Country in 2025
Figure 45. Americas Oral Polio Vaccines (OPV) Revenue Market Share by Country (2021-2026)
Figure 46. Americas Oral Polio Vaccines (OPV) Sales Market Share by Type (2021-2026)
Figure 47. Americas Oral Polio Vaccines (OPV) Sales Market Share by Application (2021-2026)
Figure 48. United States Oral Polio Vaccines (OPV) Revenue Growth 2021-2026 ($ millions)
Figure 49. Canada Oral Polio Vaccines (OPV) Revenue Growth 2021-2026 ($ millions)
Figure 50. Mexico Oral Polio Vaccines (OPV) Revenue Growth 2021-2026 ($ millions)
Figure 51. Brazil Oral Polio Vaccines (OPV) Revenue Growth 2021-2026 ($ millions)
Figure 52. APAC Oral Polio Vaccines (OPV) Sales Market Share by Region in 2025
Figure 53. APAC Oral Polio Vaccines (OPV) Revenue Market Share by Region (2021-2026)
Figure 54. APAC Oral Polio Vaccines (OPV) Sales Market Share by Type (2021-2026)
Figure 55. APAC Oral Polio Vaccines (OPV) Sales Market Share by Application (2021-2026)
Figure 56. China Oral Polio Vaccines (OPV) Revenue Growth 2021-2026 ($ millions)
Figure 57. Japan Oral Polio Vaccines (OPV) Revenue Growth 2021-2026 ($ millions)
Figure 58. South Korea Oral Polio Vaccines (OPV) Revenue Growth 2021-2026 ($ millions)
Figure 59. Southeast Asia Oral Polio Vaccines (OPV) Revenue Growth 2021-2026 ($ millions)
Figure 60. India Oral Polio Vaccines (OPV) Revenue Growth 2021-2026 ($ millions)
Figure 61. Australia Oral Polio Vaccines (OPV) Revenue Growth 2021-2026 ($ millions)
Figure 62. China Taiwan Oral Polio Vaccines (OPV) Revenue Growth 2021-2026 ($ millions)
Figure 63. Europe Oral Polio Vaccines (OPV) Sales Market Share by Country in 2025
Figure 64. Europe Oral Polio Vaccines (OPV) Revenue Market Share by Country (2021-2026)
Figure 65. Europe Oral Polio Vaccines (OPV) Sales Market Share by Type (2021-2026)
Figure 66. Europe Oral Polio Vaccines (OPV) Sales Market Share by Application (2021-2026)
Figure 67. Germany Oral Polio Vaccines (OPV) Revenue Growth 2021-2026 ($ millions)
Figure 68. France Oral Polio Vaccines (OPV) Revenue Growth 2021-2026 ($ millions)
Figure 69. UK Oral Polio Vaccines (OPV) Revenue Growth 2021-2026 ($ millions)
Figure 70. Italy Oral Polio Vaccines (OPV) Revenue Growth 2021-2026 ($ millions)
Figure 71. Russia Oral Polio Vaccines (OPV) Revenue Growth 2021-2026 ($ millions)
Figure 72. Middle East & Africa Oral Polio Vaccines (OPV) Sales Market Share by Country (2021-2026)
Figure 73. Middle East & Africa Oral Polio Vaccines (OPV) Sales Market Share by Type (2021-2026)
Figure 74. Middle East & Africa Oral Polio Vaccines (OPV) Sales Market Share by Application (2021-2026)
Figure 75. Egypt Oral Polio Vaccines (OPV) Revenue Growth 2021-2026 ($ millions)
Figure 76. South Africa Oral Polio Vaccines (OPV) Revenue Growth 2021-2026 ($ millions)
Figure 77. Israel Oral Polio Vaccines (OPV) Revenue Growth 2021-2026 ($ millions)
Figure 78. Turkey Oral Polio Vaccines (OPV) Revenue Growth 2021-2026 ($ millions)
Figure 79. GCC Countries Oral Polio Vaccines (OPV) Revenue Growth 2021-2026 ($ millions)
Figure 80. Manufacturing Cost Structure Analysis of Oral Polio Vaccines (OPV) in 2026
Figure 81. Manufacturing Process Analysis of Oral Polio Vaccines (OPV)
Figure 82. Industry Chain Structure of Oral Polio Vaccines (OPV)
Figure 83. Channels of Distribution
Figure 84. Global Oral Polio Vaccines (OPV) Sales Market Forecast by Region (2027-2032)
Figure 85. Global Oral Polio Vaccines (OPV) Revenue Market Share Forecast by Region (2027-2032)
Figure 86. Global Oral Polio Vaccines (OPV) Sales Market Share Forecast by Type (2027-2032)
Figure 87. Global Oral Polio Vaccines (OPV) Revenue Market Share Forecast by Type (2027-2032)
Figure 88. Global Oral Polio Vaccines (OPV) Sales Market Share Forecast by Application (2027-2032)
Figure 89. Global Oral Polio Vaccines (OPV) Revenue Market Share Forecast by Application (2027-2032)
Figure 1. Picture of Oral Polio Vaccines (OPV)
Figure 2. Oral Polio Vaccines (OPV) Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Oral Polio Vaccines (OPV) Sales Growth Rate 2021-2032 (K Dose)
Figure 7. Global Oral Polio Vaccines (OPV) Revenue Growth Rate 2021-2032 ($ millions)
Figure 8. Oral Polio Vaccines (OPV) Sales by Geographic Region (2021, 2025 & 2032) & ($ millions)
Figure 9. Oral Polio Vaccines (OPV) Sales Market Share by Country/Region (2025)
Figure 10. Oral Polio Vaccines (OPV) Sales Market Share by Country/Region (2021, 2025 & 2032)
Figure 11. Product Picture of Conventional OPV
Figure 12. Product Picture of Novel OPV
Figure 13. Global Oral Polio Vaccines (OPV) Sales Market Share by Type in 2026
Figure 14. Global Oral Polio Vaccines (OPV) Revenue Market Share by Type (2021-2026)
Figure 15. Product Picture of Monovalent
Figure 16. Product Picture of Bivalent
Figure 17. Product Picture of Trivalent
Figure 18. Global Oral Polio Vaccines (OPV) Sales Market Share by Virus Type in 2026
Figure 19. Global Oral Polio Vaccines (OPV) Revenue Market Share by Virus Type (2021-2026)
Figure 20. Product Picture of Oral Drops
Figure 21. Product Picture of Sugar Pill
Figure 22. Global Oral Polio Vaccines (OPV) Sales Market Share by Dosage Form in 2026
Figure 23. Global Oral Polio Vaccines (OPV) Revenue Market Share by Dosage Form (2021-2026)
Figure 24. Oral Polio Vaccines (OPV) Consumed in Public
Figure 25. Global Oral Polio Vaccines (OPV) Market: Public (2021-2026) & (K Dose)
Figure 26. Oral Polio Vaccines (OPV) Consumed in Private
Figure 27. Global Oral Polio Vaccines (OPV) Market: Private (2021-2026) & (K Dose)
Figure 28. Global Oral Polio Vaccines (OPV) Sale Market Share by Application (2025)
Figure 29. Global Oral Polio Vaccines (OPV) Revenue Market Share by Application in 2025
Figure 30. Oral Polio Vaccines (OPV) Sales by Company in 2025 (K Dose)
Figure 31. Global Oral Polio Vaccines (OPV) Sales Market Share by Company in 2025
Figure 32. Oral Polio Vaccines (OPV) Revenue by Company in 2025 ($ millions)
Figure 33. Global Oral Polio Vaccines (OPV) Revenue Market Share by Company in 2025
Figure 34. Global Oral Polio Vaccines (OPV) Sales Market Share by Geographic Region (2021-2026)
Figure 35. Global Oral Polio Vaccines (OPV) Revenue Market Share by Geographic Region in 2025
Figure 36. Americas Oral Polio Vaccines (OPV) Sales 2021-2026 (K Dose)
Figure 37. Americas Oral Polio Vaccines (OPV) Revenue 2021-2026 ($ millions)
Figure 38. APAC Oral Polio Vaccines (OPV) Sales 2021-2026 (K Dose)
Figure 39. APAC Oral Polio Vaccines (OPV) Revenue 2021-2026 ($ millions)
Figure 40. Europe Oral Polio Vaccines (OPV) Sales 2021-2026 (K Dose)
Figure 41. Europe Oral Polio Vaccines (OPV) Revenue 2021-2026 ($ millions)
Figure 42. Middle East & Africa Oral Polio Vaccines (OPV) Sales 2021-2026 (K Dose)
Figure 43. Middle East & Africa Oral Polio Vaccines (OPV) Revenue 2021-2026 ($ millions)
Figure 44. Americas Oral Polio Vaccines (OPV) Sales Market Share by Country in 2025
Figure 45. Americas Oral Polio Vaccines (OPV) Revenue Market Share by Country (2021-2026)
Figure 46. Americas Oral Polio Vaccines (OPV) Sales Market Share by Type (2021-2026)
Figure 47. Americas Oral Polio Vaccines (OPV) Sales Market Share by Application (2021-2026)
Figure 48. United States Oral Polio Vaccines (OPV) Revenue Growth 2021-2026 ($ millions)
Figure 49. Canada Oral Polio Vaccines (OPV) Revenue Growth 2021-2026 ($ millions)
Figure 50. Mexico Oral Polio Vaccines (OPV) Revenue Growth 2021-2026 ($ millions)
Figure 51. Brazil Oral Polio Vaccines (OPV) Revenue Growth 2021-2026 ($ millions)
Figure 52. APAC Oral Polio Vaccines (OPV) Sales Market Share by Region in 2025
Figure 53. APAC Oral Polio Vaccines (OPV) Revenue Market Share by Region (2021-2026)
Figure 54. APAC Oral Polio Vaccines (OPV) Sales Market Share by Type (2021-2026)
Figure 55. APAC Oral Polio Vaccines (OPV) Sales Market Share by Application (2021-2026)
Figure 56. China Oral Polio Vaccines (OPV) Revenue Growth 2021-2026 ($ millions)
Figure 57. Japan Oral Polio Vaccines (OPV) Revenue Growth 2021-2026 ($ millions)
Figure 58. South Korea Oral Polio Vaccines (OPV) Revenue Growth 2021-2026 ($ millions)
Figure 59. Southeast Asia Oral Polio Vaccines (OPV) Revenue Growth 2021-2026 ($ millions)
Figure 60. India Oral Polio Vaccines (OPV) Revenue Growth 2021-2026 ($ millions)
Figure 61. Australia Oral Polio Vaccines (OPV) Revenue Growth 2021-2026 ($ millions)
Figure 62. China Taiwan Oral Polio Vaccines (OPV) Revenue Growth 2021-2026 ($ millions)
Figure 63. Europe Oral Polio Vaccines (OPV) Sales Market Share by Country in 2025
Figure 64. Europe Oral Polio Vaccines (OPV) Revenue Market Share by Country (2021-2026)
Figure 65. Europe Oral Polio Vaccines (OPV) Sales Market Share by Type (2021-2026)
Figure 66. Europe Oral Polio Vaccines (OPV) Sales Market Share by Application (2021-2026)
Figure 67. Germany Oral Polio Vaccines (OPV) Revenue Growth 2021-2026 ($ millions)
Figure 68. France Oral Polio Vaccines (OPV) Revenue Growth 2021-2026 ($ millions)
Figure 69. UK Oral Polio Vaccines (OPV) Revenue Growth 2021-2026 ($ millions)
Figure 70. Italy Oral Polio Vaccines (OPV) Revenue Growth 2021-2026 ($ millions)
Figure 71. Russia Oral Polio Vaccines (OPV) Revenue Growth 2021-2026 ($ millions)
Figure 72. Middle East & Africa Oral Polio Vaccines (OPV) Sales Market Share by Country (2021-2026)
Figure 73. Middle East & Africa Oral Polio Vaccines (OPV) Sales Market Share by Type (2021-2026)
Figure 74. Middle East & Africa Oral Polio Vaccines (OPV) Sales Market Share by Application (2021-2026)
Figure 75. Egypt Oral Polio Vaccines (OPV) Revenue Growth 2021-2026 ($ millions)
Figure 76. South Africa Oral Polio Vaccines (OPV) Revenue Growth 2021-2026 ($ millions)
Figure 77. Israel Oral Polio Vaccines (OPV) Revenue Growth 2021-2026 ($ millions)
Figure 78. Turkey Oral Polio Vaccines (OPV) Revenue Growth 2021-2026 ($ millions)
Figure 79. GCC Countries Oral Polio Vaccines (OPV) Revenue Growth 2021-2026 ($ millions)
Figure 80. Manufacturing Cost Structure Analysis of Oral Polio Vaccines (OPV) in 2026
Figure 81. Manufacturing Process Analysis of Oral Polio Vaccines (OPV)
Figure 82. Industry Chain Structure of Oral Polio Vaccines (OPV)
Figure 83. Channels of Distribution
Figure 84. Global Oral Polio Vaccines (OPV) Sales Market Forecast by Region (2027-2032)
Figure 85. Global Oral Polio Vaccines (OPV) Revenue Market Share Forecast by Region (2027-2032)
Figure 86. Global Oral Polio Vaccines (OPV) Sales Market Share Forecast by Type (2027-2032)
Figure 87. Global Oral Polio Vaccines (OPV) Revenue Market Share Forecast by Type (2027-2032)
Figure 88. Global Oral Polio Vaccines (OPV) Sales Market Share Forecast by Application (2027-2032)
Figure 89. Global Oral Polio Vaccines (OPV) Revenue Market Share Forecast by Application (2027-2032)
